Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

PLK3 gRNA (BRDN0001146265) Citations (1)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437.
PubMed Journal

Articles Citing PLK3 gRNA (BRDN0001146265)

Articles
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3. Vaughan CA, Singh S, Subler MA, Windle JJ, Inoue K, Fry EA, Pillappa R, Grossman SR, Windle B, Andrew Yeudall W, Deb SP, Deb S. Nat Commun. 2021 Jan 29;12(1):704. doi: 10.1038/s41467-021-20928-8. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.